These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 29731479)

  • 41. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
    Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
    Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
    [TBL] [Abstract][Full Text] [Related]  

  • 43. F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging.
    Avril N; Adler LP
    Radiol Clin North Am; 2007 Jul; 45(4):645-57, vi. PubMed ID: 17706529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictive Value of
    Song BI; Kim HW; Won KS
    Ann Surg Oncol; 2017 Aug; 24(8):2174-2181. PubMed ID: 28432480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic Accuracy of Positron Emission Mammography with
    Yano F; Itoh M; Hirakawa H; Yamamoto S; Yoshikawa A; Hatazawa J
    Asia Ocean J Nucl Med Biol; 2019; 7(1):13-21. PubMed ID: 30705907
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Positron Emission Mammography Image Interpretation for Reduced Image Count Levels.
    MacDonald LR; Hippe DS; Bender LC; Cotter EW; Voria PR; Hallam PS; Wang CL; Haseley DR; Kelly MM; Parikh JR; Beatty JD; Rogers JV
    J Nucl Med; 2016 Mar; 57(3):348-54. PubMed ID: 26635337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First clinical experience with a dedicated PET for hanging breast molecular imaging.
    Koolen BB; Aukema TS; González Martínez AJ; Vogel WV; Caballero Ontanaya L; Vrancken Peeters MJ; Vroonland CJ; Rutgers EJ; Benlloch Baviera JM; Valdés Olmos RA
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):92-100. PubMed ID: 23474637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is imaging the extremities with PEM feasible? A novel application for a high-resolution positron emission scanner.
    Rahim S; Mawlawi O; Taylor S; Millican R; Swanston NM; Brown JE; Rohren EM
    Clin Imaging; 2014; 38(3):307-13. PubMed ID: 24485528
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer.
    Bassa P; Kim EE; Inoue T; Wong FC; Korkmaz M; Yang DJ; Wong WH; Hicks KW; Buzdar AU; Podoloff DA
    J Nucl Med; 1996 Jun; 37(6):931-8. PubMed ID: 8683314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clear-PEM: a dedicated PET camera for improved breast cancer detection.
    Abreu MC; Almeida P; Balau F; Ferreira NC; Fetal S; Fraga F; Martins M; Matela N; Moura R; Ortigão C; Peralta L; Rato P; Ribeiro R; Rodrigues P; Santos AI; Trindade A; Varela J
    Radiat Prot Dosimetry; 2005; 116(1-4 Pt 2):208-10. PubMed ID: 16604628
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Present and future role of FDG-PET/CT imaging in the management of breast cancer.
    Kitajima K; Miyoshi Y
    Jpn J Radiol; 2016 Mar; 34(3):167-80. PubMed ID: 26733340
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of [18F]fluorodeoxyglucose positron emission tomography-computed tomography, sonography, and sonographically guided fine-needle aspiration biopsy in the diagnosis of axillary lymph nodes in patients with breast cancer: comparison of diagnostic performance.
    Sohn YM; Hong IK; Han K
    J Ultrasound Med; 2014 Jun; 33(6):1013-21. PubMed ID: 24866608
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
    Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
    Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicentric study on ¹⁸F-FDG-PET/CT breast incidental uptake in patients studied for non-breast malignant purposes.
    Bertagna F; Evangelista L; Piccardo A; Bertoli M; Bosio G; Giubbini R; Orlando E; Treglia G
    Rev Esp Med Nucl Imagen Mol; 2015; 34(1):24-9. PubMed ID: 25312053
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diffusion-weighted imaging and (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer: Correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors.
    Karan B; Pourbagher A; Torun N
    J Magn Reson Imaging; 2016 Jun; 43(6):1434-44. PubMed ID: 26663655
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
    Melsaether AN; Raad RA; Pujara AC; Ponzo FD; Pysarenko KM; Jhaveri K; Babb JS; Sigmund EE; Kim SG; Moy LA
    Radiology; 2016 Oct; 281(1):193-202. PubMed ID: 27023002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.